G Medical Innovations Holdings Ltd

G Medical Innovations Holdings Ltd

GMVDF
G Medical Innovations Holdings LtdUS flagOther OTC
0.00
USD
- -
- -
25,992.00Market Cap
G Medical Innovations Holdings Ltd
GMVDF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
0.08
1.55
2.5
23.33
15.29
6.13
- -
Revenue per Share
- -
-20.25
-8.6
-7
-59.68
-45.49
-34.17
- -
Basic EPS, GAAP
- -
-1.12
-1.2
-3.04
-24.53
-37.12
-28.58
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
5.24
-4.1
-6.72
-357.3
-275.58
-153.19
- -
Book Value per Share
0.09
7.68
-2.75
-5.74
-14.04
-8.67
-6.34
- -
Tangible Book Value per Share
71
1
2
2
- -
- -
1
- -
Basic Weighted Avg Shares
- -
- -
3
6
5
5
4
- -
Sales/Revenue/Turnover
- -
-24,331.19
-561.2
-231.25
-251.02
-221.08
-620.14
- -
Operating Margin (%)
- -
- -
3
3
1
1
1
- -
Depreciation Expense
- -
-27
-17
-16
-13
-15
-25
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-24,822.94
-554.41
-280.66
-255.84
-297.48
-557.22
- -
Profit Margin (%)
8
12
-5
-15
-5
- -
-7
-7
Working Capital
2
3
4
2
- -
5
- -
2
LT Debt
6
13
-3
-10
-3
-3
-5
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-682.53
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'19
Mar'20
Jun'20
ST Debt
13
- -
5
LT Borrowings
1
- -
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
418
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Dec'19
Mar'20
Jun'20
Total Current Assets
2
- -
3
Cash, Cash Equivalents & STI
1
- -
1
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
17
- -
10
Payables & Accruals
4
- -
5
ST Debt
13
- -
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
29.89%
62.55%
Free Cash Flow
- -
84.85%
71.04%
Net Income, GAAP
- -
3.91%
66.89%
Sales/Revenue/Turnover
- -
553.73%
-10.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
5
2021
- -
- -
- -
- -
5
2022
- -
- -
- -
- -
4

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-59.68
2021
- -
- -
- -
- -
-45.49
2022
- -
- -
- -
- -
-34.17

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Business
G Medical Innovations Holdings Ltd is an early commercial-stage healthcare company that develops and markets next-generation mobile health (mHealth), telemedicine solutions, and remote patient monitoring service platforms. The company offers clinical- and consumer-grade products including the Prizma multi-sensor medical smartphone case that transforms smartphones into vital signs monitoring devices for measuring parameters such as ECG, blood pressure, oxygen saturation, and temperature; the G Medical Spider, a compact one-piece mobile cardiac telemetry (MCT) patch device with built-in cellular modem for real-time dual-channel ECG transmission and up to five-day battery life; the G Patch extended Holter monitoring system, a multi-channel wearable biosensor recording two- or three-lead ECG for 72 hours to 14 days with waterproof design; and Wireless Vital Signs Monitoring System for continuous real-time biometrics tracking. It also provides patient monitoring services through independent diagnostic testing facilities (IDTFs) encompassing MCT, extended Holter, event, Holter, and pacemaker analysis; extended Holter patch services; and direct-to-consumer at-home laboratory testing kits covering food sensitivities, allergies, HPV, thyroid function, testosterone levels, hemoglobin A1C, and COVID-19-related diagnostics including rapid antigen, PCR, and antibody tests; alongside accessories for its devices. Operating through Products, Patient Services, and COVID-19 Testing and Kits segments, G Medical Innovations Holdings Ltd targets healthcare providers, physicians, hospitals, and consumers to enhance care efficiency, access, and personalization, with primary revenue from patient services and activities in the United States, Israel, and other markets. Founded in 2014 and headquartered at 5 Oppenheimer Street in Rehovot, Israel, with corporate registration in the Cayman Islands, the company employs approximately 74-84 staff and maintains subsidiaries for its operations. Recent developments include a May 2024 strategic partnership with fitness expert Peter N. Nielsen to advance health and wellness innovation through collaborative projects in education, solutions, and community engagement; an ongoing alliance with MiCare Path, extended through at least December 2024, to integrate hardware with software for enhanced remote patient monitoring and patient engagement; prior collaborations such as with AdventHealth serving 5.7 million patients annually; and preparations for launches including 31 at-home testing kits by late 2023, alongside reported 194% growth in home monitoring services earlier in 2023.